Transcept Pharmaceuticals, Inc. today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Intermezzo® for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.
Transcept Pharmaceuticals, Inc. today announced that it has resubmitted its New Drug Application to the U.S. Food and Drug Administration seeking approval of Intermezzo® for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced its preliminary analysis of data from the recently completed Intermezzo® 3.5 mg (zolpidem tartrate sublingual tablet) highway driving study. Transcept is developing Intermezzo® for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. In the Intermezzo® New Drug …
Rozerem - an FDA approved sleep aid - is a new sleep therapy for the treatment of insomnia - it’s a new prescription sleep aid that’s in a class by …
Transcept Pharmaceuticals, Inc. announced today an update on its plans to seek U.S. Food and Drug Administration approval of Intermezzo® for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.  Transcept met with the FDA on January 20, 2010 to discuss the Complete Response Letter dated October 28, 2009, and received the …
